Cefmetazole, Flomoxef, and Latamoxef

Based on the search results, I'll provide comprehensive information about the combination of cefmetazole, flomoxef, and latamoxef. These three drugs are cephamycin/oxacephem antibiotics that share similar properties and are often studied together as alternatives to carbapenems for treating infections caused by extended-spectrum β-lactamase-producing bacteria (ESBL-producing bacteria). ## Drug Information Cefmetazole, flomoxef, and latamoxef (also known as moxalactam) are β-lactam antibiotics that are stable against hydrolysis by ESBLs[1]. While cefmetazole is classified as a cephamycin, flomoxef and latamoxef belong to a related class called oxacephems[4]. These antibiotics have been identified as potential carbapenem-sparing options for treating infections caused by ESBL-producing Enterobacterales[3][6]. ### Mechanism of Action These antibiotics work by inhibiting bacterial cell wall synthesis. They are stable against hydrolysis by extended-spectrum β-lactamases (ESBLs), which makes them effective against ESBL-producing bacteria[1]. However, they can be inactivated by carbapenemases and Class C β-lactamases (AmpC)[6]. ### Clinical Applications These antibiotics have been studied for treating various infections, particularly those caused by ESBL-producing Escherichia coli (ESBL-EC)[1]. They are considered potential alternatives to carbapenems for: - Urinary tract infections (UTIs)[5][6] - Intra-abdominal infections (IAIs)[6] - Bloodstream infections caused by ESBL-producing bacteria[1] Studies have shown high susceptibility rates of ESBL-EC to these antibiotics. For instance, 94.2% of ESBL-EC isolates were susceptible to cefmetazole, and 98.3% were susceptible to flomoxef in one study[1]. ### Dosage Regimens Typical dosage regimens include: - Cefmetazole: 1 g intravenously every 8 hours[1] - Flomoxef: 1 g intravenously every 8 hours[1] - Latamoxef (moxalactam): Various dosing regimens have been studied, including 20, 30, 40, 50, and 60 mg/kg in veterinary medicine[3] ### Safety Profile When cefmetazole is combined with flomoxef, there may be an increased risk of nephrotoxicity[2]. This potential interaction should be considered when administering these antibiotics together. ### Comparative Effectiveness In some studies comparing flomoxef with carbapenems for treating ESBL-producing bacterial infections, flomoxef showed comparable efficacy to carbapenems when the minimum inhibitory concentration (MIC) was low (<1 mg/L)[5]. However, for higher MIC levels (2-8 mg/L), carbapenems demonstrated superior outcomes[5]. ### Current Status Flomoxef is being proposed for inclusion on the WHO Model List of Essential Medicines (EML) and Model List of Essential Medicines for Children (EMLc) as a carbapenem-sparing option for treating infections caused by ESBL-producing bacteria[6]. It's worth noting that moxalactam is no longer in use in most countries, and latamoxef is primarily used in Japan[5]. These antibiotics represent important options in the antimicrobial armamentarium, particularly in the context of increasing antimicrobial resistance and the need for carbapenem-sparing strategies.